{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027445","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.826915+00:00","generated_at":"2026-06-11T20:55:21.806136+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProPhase Labs Q2 revenue $13.2M, down 55% YoY; adjusted EBITDA loss $2.2M","bullets":["Revenue $13.2M vs $29.1M YoY; diagnostic services fell $18.3M as COVID testing slowed.","Gross margin fell to 48.8% from 64.3%; net working capital $40.2M.","Nebula Genomics whole genome sequencing facility could generate ~$40M annual revenue at capacity.","Pharmaloz Manufacturing revenue up >50% YoY; additional lozenge line planned for early 2024.","Equivir trial enrollment commenced in India; BE-SMART test progressed with over 200 specimens."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027445","json":"https://secwatch.observer/filing/0001493152-23-027445.json","markdown":"https://secwatch.observer/filing/0001493152-23-027445.md","text":"https://secwatch.observer/filing/0001493152-23-027445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315223027445/0001493152-23-027445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315223027445/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:55:21.806136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2a0ef7b8e7ff8a8d432ea969319c6318a619278","claim":"ProPhase Labs, Inc. reported the three months ended June 30, 2023 results: net income adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million.","evidence_excerpt":"On August 10, 2023, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315223027445/0001493152-23-027445-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Net income","value":"adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}